Matinas Biopharma Hl (MTNB) 1.3000 $MTNB
Matinas BioPharma Completes Private Placement of $8.0 Million
GlobeNewswire - Tue Sep 13, 6:05AM CDT
Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company"
(OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective broad spectrum therapeutics for the treatment of serious and life-threatening infections, today announced the final closing of an $8.0 million private placement equity financing, which represents the full amount of the offering. The Company sold to accredited investors an aggregate of 1,600,000 Series A Preferred Shares at a purchase price of $5.00 per share.
Matinas BioPharma's Lead Antifungal Product Candidate MAT2203 Granted QIDP and Fast Track Designations for Prophylaxis of Invasive Fungal Infections by U.S. FDA
GlobeNewswire - Wed Sep 07, 6:05AM CDT
- Third QIDP Designation Granted by FDA for MAT2203 -
Matinas BioPharma to Present at the 18th Annual Rodman & Renshaw Global Investment Conference in New York City on September 13, 2016
GlobeNewswire - Tue Sep 06, 6:05AM CDT
Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective broad spectrum therapeutics for the treatment of serious and life-threatening infections, announced today that Jerome D. Jabbour, President, will present at the 18 Annual Rodman & Renshaw Global Investment Conference on September 13, 2016 at 3:25 p.m. ET.
Matinas BioPharma Presents Preclinical Data of MAT2501 at ASM Microbe/ICAAC 2016
GlobeNewswire - Mon Jun 20, 6:35AM CDT
Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective broad spectrum therapeutics for the treatment of serious and life-threatening infections, today presented preclinical data on its investigational drug, MAT2501 (orally-administered encochleated amikacin) for chronic and acute bacterial infections, including non-tuberculous mycobacteria (NTM) and multi-drug resistant gram-negative bacterial infections, at the American Society for Microbiology's Interscience Conference of Antimicrobial Agents and Chemotherapy (ASM Microbe/ICAAC 2016) scientific meeting being held June 16 - 20 in Boston, MA.
Matinas BioPharma Announces Acceptance of Abstract on Efficacy and Tolerability of Encochleated Ibuprofen in Rat Carrageenan-Induced Paw Inflammation Model for EULAR 2016
GlobeNewswire - Wed Jun 08, 6:00AM CDT
- Study demonstrates higher potency and better safety/tolerability of ibuprofen in lipid-crystal nano-particle formulation -
Matinas BioPharma Receives Notice of Allowance of U.S. Patent for Novel Lipid-Crystal Nano-Particle Cochleate Formulation Technology
GlobeNewswire - Wed Feb 10, 7:05AM CST
- Patent Includes Pharmaceutical Use Claims for Lead Anti-Infective Product Candidates MAT2203 (Encochleated Amphotericin
and MAT2501 (Encochleated Amikacin) -
Matinas BioPharma to Present at Biotech Showcase(TM) on January 12, 2016
GlobeNewswire - Tue Jan 05, 6:01AM CST
Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective therapeutics for the treatment of serious and life-threatening infections, announced today that it will present at the 8th Annual Biotech Showcase(TM) conference on Tuesday, January 12, 2016 at 2:30 p.m. PT in San Francisco, CA.
Matinas BioPharma Files Investigational New Drug Application With U.S. FDA for Lead Antibacterial Development Candidate MAT2501
GlobeNewswire - Mon Jan 04, 6:05AM CST
Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective therapeutics for the treatment of serious and life-threatening infections, announced today that on December 31, 2015, the Company filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for its lead antibacterial development candidate, MAT2501.
Matinas BioPharma Holdings, Inc. - MTNB Transforms The World of Anti-Infectives: Oral Delivery Beats Injection
ACCESSWIRE - Wed Dec 23, 7:47AM CST
NEW YORK, NY / ACCESSWIRE / December 23, 2015 / Matinas BioPharma Holdings, Inc. (OTCQB: MTNB) today published a series of blog posts on The Chairman's Blog, written by the Company's Chief Executive Officer, Dr. Roelof Rongen and Chief Technology Officer, Dr. Raphael Mannino. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Matinas BioPharma's Lead Antifungal Product Candidate MAT2203 Granted QIDP and Fast Track Designations for Treatment of Aspergillus by U.S. FDA
GlobeNewswire - Thu Dec 17, 6:05AM CST
Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective therapeutics for the treatment of serious and life-threatening infections, today announced that the U.S. Food and Drug Administration (FDA) has designated the Company's lead drug candidate MAT2203 as a Qualified Infectious Disease Product (QIDP) with Fast Track status for the treatment of aspergillus.
Matinas BioPharma to Present at the 8th Annual LD Micro Main Event on December 3, 2015
GlobeNewswire - Thu Nov 19, 6:05AM CST
Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective therapeutics for the treatment of serious and life-threatening infections, today announced that it will present at the 8 Annual LD Micro Main Event on December 3, 2015, at 8:30 a.m. Pacific Time (11:30 a.m. Eastern Time) at the Luxe Sunset Hotel in Los Angeles, CA.
Matinas BioPharma Reports 2015 Third Quarter Financial Results and Provides Business Update
GlobeNewswire - Tue Nov 10, 6:35AM CST
- Topline data from Phase 2a clinical trial with MAT2203, oral encochleated amphotericin B, expected in 2016 -
Matinas BioPharma Receives Notice of Allowance of U.S. Patent for Encochleated siRNA
GlobeNewswire - Mon Oct 26, 7:05AM CDT
Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective therapeutics for the treatment of serious and life-threatening infections, today announced that it received a Notice of Allowance from the U.S. Patent and Trademark Office ("USPTO" for U.S. Patent Application Serial No. 14/038,810 entitled, "Cochleate Compositions Directed Against Expression of Proteins."
Matinas BioPharma Selected to Present at Cavendish Global Health Impact Forum
GlobeNewswire - Thu Oct 22, 7:05AM CDT
Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective therapeutics for the treatment of serious and life-threatening infections, today announced that it has been selected as a Cavendish Innovation Partner and will present at the Cavendish Global Health Impact Forum co-hosted by The Cleveland Clinic, which takes place October 25 to October 28 at The Cleveland Clinic, Cleveland, Ohio.
Matinas BioPharma to Present at the 14th Annual BIO Investor Forum on October 20, 2015
GlobeNewswire - Wed Oct 14, 6:05AM CDT
Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective therapeutics for the treatment of serious and life-threatening infections, today announced that it will be presenting at the 14 Annual BIO Investor Forum being held October 20-21, 2015, at the Parc 55 in San Francisco, California.
Matinas BioPharma Presents Preclinical PK and Efficacy Data of Encochleated Atovaquone in Murine Model at IDWeek 2015
GlobeNewswire - Sat Oct 10, 7:00AM CDT
- CATQ - Encochleated Atovaquone - Demonstrates Enhanced Efficacy and Tissue Targeting over Current Formulation -
MarketExclusive.com - Maxim Group Reiterates BUY Rating for Matinas BioPharma Holdings, Inc. and Provides Company Update
ACCESSWIRE - Mon Oct 05, 1:04PM CDT
NEW YORK, NY / ACCESSWIRE / October 5, 2015 / Market Exclusive announces that Maxim Group has reiterated a Buy rating for Matinas BioPharma Holdings, Inc. (OTCQB:MTNB) with a 12-month price target of $6.00 per share. The analyst note was published following the announcement that Matinas has received IRB approval to commence a NIH-Sponsored Phase 2a study with MAT2203.
Matinas BioPharma Receives Institutional Review Board Approval to Commence NIH-Sponsored Phase 2a Study With MAT2203 - An Orally Delivered, Encochleated Formulation of Amphotericin B -
GlobeNewswire - Mon Oct 05, 6:00AM CDT
- NIH IRB Approves Study of MAT2203 - Oral, Encochleated Formulation of Amphotericin B -
Matinas BioPharma Presents Pre-clinical Data Showing Anti-bacterial Activity of MAT2501 - Encochleated Amikacin - Against Mycobacterium Avium Lung Infections at ICAAC/ICC 2015
GlobeNewswire - Sat Sep 19, 1:00PM CDT
Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective antifungal and anti-bacterial therapeutics for the treatment of serious and life-threatening infections, today presented preclinical data showing significant anti-bacterial activity against Mycobacterium avium (M. avium) and no noted toxicity by MAT2501, an orally-administered encochleated formulation of amikacin.
Matinas BioPharma's MAT2203 -- Encochleated Formulation of Amphotericin B -- Shows Potential to Target and Penetrate Tissue Infected With Invasive Candidiasis in Data Presented at ICAAC/ICC 2015
GlobeNewswire - Fri Sep 18, 2:06PM CDT
Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective antifungal and anti-bacterial therapeutics for the treatment of serious and life-threatening infections, today presented data from a preclinical study demonstrating tissue targeting and penetration potential of MAT2203, an orally-administered, encochleated formulation of the broad spectrum antifungal medication amphotericin B (AmB).
Matinas BioPharma Completes Private Placement of $8.0 Million
GlobeNewswire - Tue Sep 13, 6:05AM CDT
Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company"
(OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective broad spectrum therapeutics for the treatment of serious and life-threatening infections, today announced the final closing of an $8.0 million private placement equity financing, which represents the full amount of the offering. The Company sold to accredited investors an aggregate of 1,600,000 Series A Preferred Shares at a purchase price of $5.00 per share. Matinas BioPharma's Lead Antifungal Product Candidate MAT2203 Granted QIDP and Fast Track Designations for Prophylaxis of Invasive Fungal Infections by U.S. FDA
GlobeNewswire - Wed Sep 07, 6:05AM CDT
- Third QIDP Designation Granted by FDA for MAT2203 -
Matinas BioPharma to Present at the 18th Annual Rodman & Renshaw Global Investment Conference in New York City on September 13, 2016
GlobeNewswire - Tue Sep 06, 6:05AM CDT
Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective broad spectrum therapeutics for the treatment of serious and life-threatening infections, announced today that Jerome D. Jabbour, President, will present at the 18 Annual Rodman & Renshaw Global Investment Conference on September 13, 2016 at 3:25 p.m. ET.
Matinas BioPharma Presents Preclinical Data of MAT2501 at ASM Microbe/ICAAC 2016
GlobeNewswire - Mon Jun 20, 6:35AM CDT
Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective broad spectrum therapeutics for the treatment of serious and life-threatening infections, today presented preclinical data on its investigational drug, MAT2501 (orally-administered encochleated amikacin) for chronic and acute bacterial infections, including non-tuberculous mycobacteria (NTM) and multi-drug resistant gram-negative bacterial infections, at the American Society for Microbiology's Interscience Conference of Antimicrobial Agents and Chemotherapy (ASM Microbe/ICAAC 2016) scientific meeting being held June 16 - 20 in Boston, MA.
Matinas BioPharma Announces Acceptance of Abstract on Efficacy and Tolerability of Encochleated Ibuprofen in Rat Carrageenan-Induced Paw Inflammation Model for EULAR 2016
GlobeNewswire - Wed Jun 08, 6:00AM CDT
- Study demonstrates higher potency and better safety/tolerability of ibuprofen in lipid-crystal nano-particle formulation -
Matinas BioPharma Receives Notice of Allowance of U.S. Patent for Novel Lipid-Crystal Nano-Particle Cochleate Formulation Technology
GlobeNewswire - Wed Feb 10, 7:05AM CST
- Patent Includes Pharmaceutical Use Claims for Lead Anti-Infective Product Candidates MAT2203 (Encochleated Amphotericin
and MAT2501 (Encochleated Amikacin) - Matinas BioPharma to Present at Biotech Showcase(TM) on January 12, 2016
GlobeNewswire - Tue Jan 05, 6:01AM CST
Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective therapeutics for the treatment of serious and life-threatening infections, announced today that it will present at the 8th Annual Biotech Showcase(TM) conference on Tuesday, January 12, 2016 at 2:30 p.m. PT in San Francisco, CA.
Matinas BioPharma Files Investigational New Drug Application With U.S. FDA for Lead Antibacterial Development Candidate MAT2501
GlobeNewswire - Mon Jan 04, 6:05AM CST
Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective therapeutics for the treatment of serious and life-threatening infections, announced today that on December 31, 2015, the Company filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for its lead antibacterial development candidate, MAT2501.
Matinas BioPharma Holdings, Inc. - MTNB Transforms The World of Anti-Infectives: Oral Delivery Beats Injection
ACCESSWIRE - Wed Dec 23, 7:47AM CST
NEW YORK, NY / ACCESSWIRE / December 23, 2015 / Matinas BioPharma Holdings, Inc. (OTCQB: MTNB) today published a series of blog posts on The Chairman's Blog, written by the Company's Chief Executive Officer, Dr. Roelof Rongen and Chief Technology Officer, Dr. Raphael Mannino. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Matinas BioPharma's Lead Antifungal Product Candidate MAT2203 Granted QIDP and Fast Track Designations for Treatment of Aspergillus by U.S. FDA
GlobeNewswire - Thu Dec 17, 6:05AM CST
Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective therapeutics for the treatment of serious and life-threatening infections, today announced that the U.S. Food and Drug Administration (FDA) has designated the Company's lead drug candidate MAT2203 as a Qualified Infectious Disease Product (QIDP) with Fast Track status for the treatment of aspergillus.
Matinas BioPharma to Present at the 8th Annual LD Micro Main Event on December 3, 2015
GlobeNewswire - Thu Nov 19, 6:05AM CST
Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective therapeutics for the treatment of serious and life-threatening infections, today announced that it will present at the 8 Annual LD Micro Main Event on December 3, 2015, at 8:30 a.m. Pacific Time (11:30 a.m. Eastern Time) at the Luxe Sunset Hotel in Los Angeles, CA.
Matinas BioPharma Reports 2015 Third Quarter Financial Results and Provides Business Update
GlobeNewswire - Tue Nov 10, 6:35AM CST
- Topline data from Phase 2a clinical trial with MAT2203, oral encochleated amphotericin B, expected in 2016 -
Matinas BioPharma Receives Notice of Allowance of U.S. Patent for Encochleated siRNA
GlobeNewswire - Mon Oct 26, 7:05AM CDT
Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective therapeutics for the treatment of serious and life-threatening infections, today announced that it received a Notice of Allowance from the U.S. Patent and Trademark Office ("USPTO"
for U.S. Patent Application Serial No. 14/038,810 entitled, "Cochleate Compositions Directed Against Expression of Proteins." Matinas BioPharma Selected to Present at Cavendish Global Health Impact Forum
GlobeNewswire - Thu Oct 22, 7:05AM CDT
Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective therapeutics for the treatment of serious and life-threatening infections, today announced that it has been selected as a Cavendish Innovation Partner and will present at the Cavendish Global Health Impact Forum co-hosted by The Cleveland Clinic, which takes place October 25 to October 28 at The Cleveland Clinic, Cleveland, Ohio.
Matinas BioPharma to Present at the 14th Annual BIO Investor Forum on October 20, 2015
GlobeNewswire - Wed Oct 14, 6:05AM CDT
Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective therapeutics for the treatment of serious and life-threatening infections, today announced that it will be presenting at the 14 Annual BIO Investor Forum being held October 20-21, 2015, at the Parc 55 in San Francisco, California.
Matinas BioPharma Presents Preclinical PK and Efficacy Data of Encochleated Atovaquone in Murine Model at IDWeek 2015
GlobeNewswire - Sat Oct 10, 7:00AM CDT
- CATQ - Encochleated Atovaquone - Demonstrates Enhanced Efficacy and Tissue Targeting over Current Formulation -
MarketExclusive.com - Maxim Group Reiterates BUY Rating for Matinas BioPharma Holdings, Inc. and Provides Company Update
ACCESSWIRE - Mon Oct 05, 1:04PM CDT
NEW YORK, NY / ACCESSWIRE / October 5, 2015 / Market Exclusive announces that Maxim Group has reiterated a Buy rating for Matinas BioPharma Holdings, Inc. (OTCQB:MTNB) with a 12-month price target of $6.00 per share. The analyst note was published following the announcement that Matinas has received IRB approval to commence a NIH-Sponsored Phase 2a study with MAT2203.
Matinas BioPharma Receives Institutional Review Board Approval to Commence NIH-Sponsored Phase 2a Study With MAT2203 - An Orally Delivered, Encochleated Formulation of Amphotericin B -
GlobeNewswire - Mon Oct 05, 6:00AM CDT
- NIH IRB Approves Study of MAT2203 - Oral, Encochleated Formulation of Amphotericin B -
Matinas BioPharma Presents Pre-clinical Data Showing Anti-bacterial Activity of MAT2501 - Encochleated Amikacin - Against Mycobacterium Avium Lung Infections at ICAAC/ICC 2015
GlobeNewswire - Sat Sep 19, 1:00PM CDT
Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective antifungal and anti-bacterial therapeutics for the treatment of serious and life-threatening infections, today presented preclinical data showing significant anti-bacterial activity against Mycobacterium avium (M. avium) and no noted toxicity by MAT2501, an orally-administered encochleated formulation of amikacin.
Matinas BioPharma's MAT2203 -- Encochleated Formulation of Amphotericin B -- Shows Potential to Target and Penetrate Tissue Infected With Invasive Candidiasis in Data Presented at ICAAC/ICC 2015
GlobeNewswire - Fri Sep 18, 2:06PM CDT
Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective antifungal and anti-bacterial therapeutics for the treatment of serious and life-threatening infections, today presented data from a preclinical study demonstrating tissue targeting and penetration potential of MAT2203, an orally-administered, encochleated formulation of the broad spectrum antifungal medication amphotericin B (AmB).
